胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的疗效观察

Intrapleural injection of recombinant human adenovirus type 5 in the treatment of malignant pleural effusion in advanced lung cancer

目的探讨胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的临床疗效。方法选择我院收治的晚期肺癌恶性胸腔积液患者50例,随机分为观察组和对照组各25例。对照组患者给予胸腔注射顺铂,观察组患者给予胸腔注射重组人5型腺病毒,比较两组患者临床疗效、生活方式评分以及不良反应发生情况。结果观察组总有效率为72.00%,明显高于对照组的52.00%(P<0.05);治疗后,观察组患者的生活方式各项因素评分均明显高于对照组,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论胸腔内注射重组人5型腺病毒治疗晚期肺癌恶性胸腔积液的临床效果显著,能有效提高患者的生活质量,且不良反应少,值得推广应用。

Objective To investigate the clinical efficacy of intrapleural injection of recombinant human adenovirus type 5 in the treatment of malignant pleural effusion in advanced lung cancer. Methods 50 cases of advanced malignant pleural effusion in our hospital were selected,the patients were randomly divided into observation group and control group with 25 cases in each group.Patients in the control group received intrapleural injections of cisplatin,the patients in the observation group were injected with recombinant human adenovirus type 5.The clinical efficacy,lifestyle score and adverse reactions were compared between the two groups. Results The total effective rate of the observation group was 72.00%,significantly higher than that of the control group 52.00%(P<0.05);after treatment,the scores of lifestyle factors in the observation group were significantly higher than those in the control group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Intrapleural injection of recombinant human adenovirus type 5 is effective in the treatment of advanced malignant pleural effusion of lung cancer,can effectively improve the quality of life of patients,and less adverse reactions,it is worth popularizing.